United Therapeutics (UTHR) CEO sells 9,500 shares after option exercise
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options for 9,500 shares of common stock at $135.4200 per share and sold 9,500 shares in open-market trades on July 13, 2026, with reported prices including $542.8000 and $533.7022 per share. The exercise and sales were carried out under a pre-arranged 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of exercising 1,734,410 stock options expiring March 15, 2027 or December 31, 2026. After these transactions, Rothblatt holds 50,013 shares directly, plus additional indirect common stock and stock option positions in family trusts and a spouse account, including stock options over 349,192 underlying shares at a $135.4200 exercise price expiring March 15, 2027.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 9,500 shares ($5,091,949)
Net Sell
17 txns
Insider
ROTHBLATT MARTINE A
Role
Chairperson & CEO
Sold
9,500 shs ($5.09M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 9,500 | $0.00 | -- |
| Exercise | Common Stock | 9,500 | $135.42 | $1.29M |
| Sale | Common Stock | 1,020 | $533.7022 | $544K |
| Sale | Common Stock | 2,272 | $534.6256 | $1.21M |
| Sale | Common Stock | 2,191 | $535.4694 | $1.17M |
| Sale | Common Stock | 2,223 | $536.5157 | $1.19M |
| Sale | Common Stock | 665 | $537.6622 | $358K |
| Sale | Common Stock | 409 | $538.6047 | $220K |
| Sale | Common Stock | 320 | $539.6044 | $173K |
| Sale | Common Stock | 360 | $541.0997 | $195K |
| Sale | Common Stock | 40 | $542.80 | $22K |
| holding | Stock Options | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option — 11,218 shares (Direct);
Common Stock — 50,013 shares (Direct);
Stock Options — 349,192 shares (Indirect, by Trust);
Common Stock — 166 shares (Indirect, by Spouse)
Footnotes (1)
- This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries. This transaction was executed in multiple trades at prices ranging from $533.04 to $534.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $534.05 to $535.04. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $535.05 to $536.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $536.05 to $537.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $537.09 to $538.04. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $538.10 to $539.095. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $539.25 to $540.18. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $540.57 to $541.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Shares sold: 9,500 shares
Sale price example: $542.8000 per share
Lowest reported sale price: $533.7022 per share
+6 more
9 metrics
Shares sold
9,500 shares
Open-market sales of common stock on July 13, 2026 by the CEO
Sale price example
$542.8000 per share
Price for 40 common shares sold on July 13, 2026
Lowest reported sale price
$533.7022 per share
Price for 1,020 common shares sold on July 13, 2026
Options exercised
9,500 shares
Common shares obtained by exercising stock options at $135.4200
Option exercise price
$135.4200 per share
Exercise price of the CEO’s stock options expiring March 15, 2027
Direct shares after transactions
50,013 shares
Common stock held directly by Martine A. Rothblatt after July 13, 2026
Direct options remaining
11,218 options
Stock options held directly after partial exercise, expiring March 15, 2027
Indirect option underlying shares
349,192 underlying shares
Common shares underlying indirect stock options at $135.4200, expiring March 15, 2027
Plan option capacity
1,734,410 stock options
Maximum options to be exercised under the 10b5-1 trading plan
Key Terms
10b5-1 trading plan, weighted average price, family trusts, exercise of stock options, +1 more
5 terms
10b5-1 trading plan regulatory
"This exercise of stock options and sale ... was pursuant to a pre-arranged 10b5-1 trading plan"
A 10b5-1 trading plan is a pre-arranged strategy that allows company insiders to buy or sell company stock at set times, regardless of their current knowledge about the company's situation. It acts like a scheduled appointment for trading, helping prevent the appearance of impropriety or insider trading. This plan provides a way for insiders to sell or buy shares in a controlled, transparent manner, offering reassurance to investors about fair trading practices.
weighted average price financial
"The price reported above reflects the weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
family trusts financial
"Shares held in family trusts as to which the Reporting Person shares investment power"
exercise of stock options financial
"This exercise of stock options and sale of the resulting shares of common stock"
investment power financial
"Shares held in family trusts as to which the Reporting Person shares investment power"
FAQ
What insider transactions did United Therapeutics (UTHR) CEO Martine Rothblatt report for July 13, 2026?
Martine A. Rothblatt exercised 9,500 stock options at $135.4200 per share and sold 9,500 common shares in open-market transactions on July 13, 2026, under a pre-arranged 10b5-1 trading plan adopted in November 2025.
What stock options in United Therapeutics (UTHR) does Martine Rothblatt retain following the reported transactions?
Following a partial exercise, Rothblatt holds 11,218 stock options directly, each with a $135.4200 exercise price and a March 15, 2027 expiration. Indirectly, family trusts hold stock options over 349,192 underlying common shares at the same exercise price and expiration date.
What is the scale of the 10b5-1 trading plan involving United Therapeutics (UTHR) stock options?
The 10b5-1 trading plan covers up to 1,734,410 stock options, all expiring on March 15, 2027. It is structured to continue until those options are exercised or until December 31, 2026, whichever occurs first, guiding ongoing option exercises and related share sales.